Prioritizing drug targets for Alzheimer’s Disease using a Mendelian Randomization framework integrating neuroimaging and genomics

Alzheimer’s Disease is a progressive neurodegenerative disorder that currently has no disease‐modifying treatment, partly due to inefficiencies in identifying and validating drug targets. Drugs with genetic support are more likely to succeed in pharmaceutical trials. Recent studies show that in vivo neuroimaging can capture changes in brain pathology and function before onset of cognitive symptoms, thereby serving as biomarkers for early diagnosis. Pharmaceutical intervention may be more effective if treatment is started earlier in the disease course. We aim to integrate imaging and genomic data to identify and prioritize gene targets for Alzheimer’s Disease treatment.